EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Peptide antagonists of the renin angiotensin system in the characterization of receptors for angiotensin induced drinking






Brain Research 153(2): 319-331

Peptide antagonists of the renin angiotensin system in the characterization of receptors for angiotensin induced drinking

The 2 naturally occurring analogs of angiotensin II (AII), Asp1-Val5-AII and Asp1-Ile5-AII, were equally effective as intracranial dipsogens in the water-replete rat. Renin, synthetic tetradecapeptide renin substrate (SRS) and angiotensin I (AI) also produced copious drinking when injected into the brain, but the naturally occurring renin substrate of rat caused little drinking and was much less effective than SRS. Prior intracranial injection of pepstatin, a competitive antagonist of the renin-angiotensinogen reaction, reduced drinking in response to renin and SRS but not to AI and AII. Renin-, SRS-and AI-induced drinking were inhibited by the converting enzyme inhibitor SQ 20881 [teprotide] injected through the same intracranial cannula in antagonist to agonist ratio of 1000:1, whereas the AII response was enhanced, although not significantly so, and the carbachol response was unaffected. Position 8 aliphatic substituted analogs of AII were competitive antagonists of AII-induced drinking, and also inhibited drinking induced by renin, SRS and AI injected through the same intracranial cannula, but they did not inhibit carbachol-induced drinking. The angiotensin-sensitive receptor for thirst does not accept SRS or AI, but responds best to AII.

(PDF 0-2 workdays service: $29.90)

Accession: 006079643

PMID: 210883



Related references

Peptide antagonists of the renin-angiotensin system and the elucidation of the receptors for angiotensin-induced drinking. Journal of Physiology 238(1): 34p-35p, 1974

Peptide antagonists of the renin-angiotensin system in the characterisation of receptors for angiotensin-induced drinking. Brain Research 153(2): 319-331, 1978

Peptide receptors i nonpeptide angiotensin ii receptor antagonists a novel way to inhibit the renin angiotensin system with therapeutic potential. Senior Advisory Group on Biotechnology Biotechnology International, 1992 436p Century Press: London, England, Uk Illus Paper 334-339, 1991

Inhibition of renin-angiotensin induced drinking in the cat by enzyme inhibitors and by analogue antagonists of angiotensin II. Clinical and Experimental Pharmacology and Physiology 1(5): 389-396, 1974

Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system. Journal of Hypertension. Supplement 10(7): S157-S164, 1992

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension 22(12): 2253-2261, 2004

Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists. Journal of Clinical Hypertension 4(6 Suppl 2): 11-9, 31, 2002

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109(21): 2492-2499, 2004

Interrupting the renin-angiotensin system: The role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. American Journal of Hypertension 12(12 part 3): 189S-194S, 1999

Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. American Journal of Hypertension 12(12 Pt 3): 189s-194s, 2000